Synthetic analog · 29 amino acids · 4,231.6 Da

Survodutide studies and research data

PepBank has 27 survodutide studies with results. 23 of them gave survodutide, with 172 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 172 results and 101 papers. Newer studies from Europe PMC

Results in people

137

80% of 172 results

Results in animals

19% of 172 results

Results in lab cells

1% of 172 results

From computer models

0% of 172 results

The molecule

Survodutide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Survodutide (BI 456906) is a 29-residue synthetic peptide designed by adding GLP-1 receptor activity to the glucagon sequence (Zimmermann et al. 2022). It has 1-aminocyclobutane-1-carboxylic acid (Ac4c) at position 2, a C-terminal amide and a C18 fatty diacid on Lys24, attached through L-gamma-Glu and a Gly-Ser-Gly-Ser-Gly-Gly linker (GSRS). It is a glucagon receptor and GLP-1 receptor dual agonist. Boehringer Ingelheim develops it under license from Zealand Pharma; it is in phase 3 trials for obesity and MASH, and no approval was found in Drugs@FDA or the EMA data on 2026-10-09.

Kind: Synthetic analog · 29 residues
Identifiers: ChEMBLCHEMBL5314776 (opens in a new tab)PubChem CID171378821 (opens in a new tab)168429725 (opens in a new tab)UNII2ALA66NS64 (opens in a new tab)DrugBankDB18989 (opens in a new tab)CAS2805997-46-8KEGGD12898 (opens in a new tab)IUPHAR13383 (opens in a new tab)
Parent: Analog of Glucagon, humanZimmermann et al. 2022 (Mol Metab, PMID 36356832): BI 456906 was designed 'by introducing GLP-1R activity into the glucagon amino acid sequence'. Substitutions are a direct alignment with human glucagon (UniProt P01275, residues 53-81). Survodutide also has a C-terminal amide; glucagon has a free acid.
Development: Phase 3Boehringer Ingelheim (licensed from Zealand Pharma)Global phase 3 programs SYNCHRONIZE (obesity and overweight; ClinicalTrials.gov lists SYNCHRONIZE-1, -2, -MASLD, -CVOT, -JP, a China study, and the not-yet-recruiting SYNCHRONIZE-START and SYNCHRONIZE-HERA) and LIVERAGE (MASH, including LIVERAGE-Cirrhosis). The Zealand Pharma pipeline page (read before 2026-10-09; it returned HTTP 403 on that date) states that survodutide has not been evaluated or approved for marketing by any regulatory authority. ClinicalTrials.gov lists 36 studies (12 phase 3) for query.intr=survodutide OR "BI 456906". ChEMBL max_phase 3. No marketing application for survodutide was found on 2026-10-09 (no Drugs@FDA record; no EMA record). Source (opens in a new tab)The note counts 36 studies from a registry search made when the note was written, with its own search terms. PepBank links 35 registered trials to Survodutide today, so the two numbers differ.

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Glucagon receptorGCGRP47871 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)
Glucagon-like peptide 1 receptorGLP1RP43220 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

29 amino acids · 3 modifications

H-

HQGTFTSDY

SKYLDERAAK

DFIWLESA

Alignment to Glucagon

Calculated from the two sequences. Curated notes are shown as given.

20 of 29 aligned residues identical (69%) · 8 substitutions · 1 non-canonical residue · Glucagon 1–29

Top row: Glucagon (parent)
Bottom row: Survodutide

HQGTFTSDY

SKYLDRA

DFWL

Same as parent
Substituted
Non-canonical or D-form
Added
Gap
Modified side chain or end

Differences from the parent

1Parent 2 · analog 2Ser → Ac4c · Non-canonical residueProteolytic stability (Zimmermann et al. 2022). 1-aminocyclobutane-1-carboxylic acid (GSRS name: 1-aminocyclobutanecarbonyl). Zimmermann et al. 2022: the position 2 exchange gives resistance to proteolytic cleavage.
2Parent 16 · analog 16Ser → Glu · Substitution
3Parent 18 · analog 18Arg → Ala · Substitution
4Parent 20 · analog 20Gln → Lys · Substitution
5Parent 23 · analog 23Val → Ile · Substitution
6Parent 24 · analog 24Gln → Lys · SubstitutionLys24 carries the linker and C18 diacid. N6 carries, from Lys outward: Gly-Gly-Ser-Gly-Ser-Gly, L-gamma-Glu, then 17-carboxyheptadecanoyl (C18 fatty diacid). GSRS models the linker as a second subunit GSGSGG with fragment ADS5D64S87; KEGG D12898 shows it as chain B EGSGSGG with an amide bridge A24-B7.
7Parent 27 · analog 27Met → Glu · Substitution
8Parent 28 · analog 28Asn → Ser · Substitution
9Parent 29 · analog 29Thr → Ala · SubstitutionC-terminal alaninamide (GSRS systematic name).

Basis: Zimmermann et al. 2022 (Mol Metab, PMID 36356832): BI 456906 was designed 'by introducing GLP-1R activity into the glucagon amino acid sequence'. Substitutions are a direct alignment with human glucagon (UniProt P01275, residues 53-81). Survodutide also has a C-terminal amide; glucagon has a free acid.

Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.

Properties

From identity sources

Formula: C₁₉₂H₂₈₉N₄₇O₆₁
Molecular weight: 4,231.63 g/mol
Monoisotopic mass: 4,229.0957 Da

GSRS UNII 2ALA66NS64(opens in a new tab)retrieved 2026-10-08
GSRS UNII ADS5D64S87(opens in a new tab)retrieved 2026-10-08
PubChem CID 171378821(opens in a new tab)retrieved 2026-10-08
PubChem CID 168429725(opens in a new tab)retrieved 2026-10-08
ChEMBL CHEMBL5314776(opens in a new tab)retrieved 2026-10-08
Curated KEGG D12898(opens in a new tab)retrieved 2026-10-08

Calculated from the sequence

pKa set

Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): Not calculated
Extinction coefficient, 280 nm (Cys reduced): 8,480 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: Not calculated
Aliphatic index: Not calculated
Boman index: Not calculated
Hydrophobic moment (μH): Not calculated

1 non-canonical residue (X) is not included in calculated values.
Not included: lipid chain. Mass, charge and pI are not calculated; use the identity-source values.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Composition

Hydrophobic21% (6)A I L
Aromatic17% (5)F W Y
Positive17% (5)H K R
Negative17% (5)D E
Polar21% (6)Q S T
Special3% (1)G
Non-canonical3% (1)X

29 residues. Each residue counts in one class; F and W count as aromatic.

A Ala3 · 10%

I Ile1 · 3%

L Leu2 · 7%

M Met0 · 0%

V Val0 · 0%

F Phe2 · 7%

W Trp1 · 3%

Y Tyr2 · 7%

H His1 · 3%

K Lys3 · 10%

R Arg1 · 3%

D Asp3 · 10%

E Glu2 · 7%

N Asn0 · 0%

Q Gln1 · 3%

S Ser3 · 10%

T Thr2 · 7%

C Cys0 · 0%

G Gly1 · 3%

P Pro0 · 0%

X Xaa1 · 3%

3D structure

PredictedAlphaFold DB · P01275

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Survodutide has 29 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 171378821(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C7(CCC7)NC(=O)[C@H](CC8=CNC=N8)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.281
μH, best 11-residue window: —
Arrow direction: 294°
Residues: 29 · 2 rings of 18 · 1 X not scored

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	H	0°	-0.40
2	X	100°	not scored
3	Q	200°	-0.85
4	G	300°	0.48
5	T	40°	-0.05
6	F	140°	1.19
7	T	240°	-0.05
8	S	340°	-0.18
9	D	80°	-0.90
10	Y	180°	0.26
11	S	280°	-0.18
12	K	20°	-1.50
13	Y	120°	0.26
14	L	220°	1.06
15	D	320°	-0.90
16	E	60°	-0.74
17	R	160°	-2.53
18	A	260°	0.62
19	A	0°	0.62
20	K	100°	-1.50
21	D	200°	-0.90
22	F	300°	1.19
23	I	40°	1.38
24	K	140°	-1.50
25	W	240°	0.81
26	L	340°	1.06
27	E	80°	-0.74
28	S	180°	-0.18
29	A	280°	0.62

Results by area

Survodutide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

27 of 101 studies have results (27%), published 2022 to 2026. Top row: every study. Bottom row: studies with results about Survodutide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies101 in all, 2022 to 2026

Studies with results27 in all, 2022 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Survodutide studies on weight and appetite

44 results · people 38 · animals 6 · lab 0

Top 5 of 44 results

In adults with obesity, survodutide at up to 3.6 mg weekly reduced body weight more than placebo after 76 weeks.The New England journal of medicine, 2026
In mice, BI 456906 reduced food intake, which helped explain its stronger weight loss.Molecular metabolism, 2022
In mice, survodutide activated several brain regions that help control food intake.Molecular metabolism, 2026
In adults with obesity and type 2 diabetes, survodutide 3.6 mg weekly led to more weight loss than placebo at week 76.The New England journal of medicine, 2026
In Japanese men with overweight or obesity, BI 456906 at up to 1.8 mg weekly lowered body weight more than placebo after 16 weeks.Diabetes, obesity & metabolism, 2023

Survodutide studies on side effects

36 results · people 36 · animals 0 · lab 0

Top 5 of 36 results

In adults with MASH, nausea was more common with survodutide (66%) than with placebo (23%).The New England journal of medicine, 2024
In Japanese men with overweight or obesity, some people on BI 456906 stopped dose increases because of side effects. No one on placebo did.Diabetes, obesity & metabolism, 2023
In adults with MASH, serious side effects occurred in 8% on survodutide and 7% on placebo.The New England journal of medicine, 2024
In a 6-week multiple-dose study, six people stopped BI 456906 because of a heart or blood vessel side effect.Diabetes, obesity & metabolism, 2023
In a 16-week multiple-dose study, six people stopped BI 456906 because of side effects, mostly stomach and gut problems.Diabetes, obesity & metabolism, 2023

Survodutide studies on liver

29 results · people 28 · animals 1 · lab 0

Top 3 of 29 results

In adults with MASH, more people improved on survodutide 2.4 mg (47%) than on placebo (14%).The New England journal of medicine, 2024
In adults with MASH, about two thirds of survodutide's effect on MASH resolution was explained by weight loss.Hepatology, 2026
In a pooled analysis of trials in people with MASH, survodutide improved liver scarring more often than placebo.Hepatology, 2025

Survodutide studies on blood sugar

30 results · people 23 · animals 7 · lab 0

Top 5 of 30 results

In adults with overweight or obesity and normal glucose, survodutide did not significantly change HOMA-β compared with placebo.Diabetes, obesity & metabolism, 2026
In a pooled analysis of adult trials, survodutide lowered fasting glucagon levels more than placebo.Diabetes, obesity & metabolism, 2025
In adults with obesity and type 2 diabetes, survodutide 3.6 mg weekly lowered HbA1c more than placebo.The New England journal of medicine, 2026
In mice with advanced diabetic kidney disease, survodutide improved high insulin levels compared with vehicle.Diabetes, obesity & metabolism, 2026
In a pooled analysis of adult trials, survodutide lowered HbA1c more than placebo.Diabetes, obesity & metabolism, 2025

Survodutide studies on receptors and cell signals

18 results · people 5 · animals 11 · lab 2

Top 5 of 18 results

In Japanese men, BI 456906 lowered blood alanine, which suggests the drug acts on its target receptors.Diabetes, obesity & metabolism, 2023
In Japanese men on BI 456906, paracetamol absorption fell in the first week at two dose levels, which points to briefly slower stomach emptying.Diabetes, obesity & metabolism, 2023
In mice, a liver gene marker showed that BI 456906 acts on the glucagon receptor.Molecular metabolism, 2022
In mice, survodutide reached brain regions near the blood-brain barrier that control appetite, but did not clearly enter the whole brain.Molecular metabolism, 2026
In people given BI 456906, blood amino acids fell, which suggests the drug acts on its target receptors.Diabetes, obesity & metabolism, 2023

Survodutide studies on blood levels and clearance

3 results · people 3 · animals 0 · lab 0

3 results

In Japanese men with overweight or obesity, blood levels of BI 456906 rose with higher doses.Diabetes, obesity & metabolism, 2023
After one dose, the amount of survodutide in the blood was similar in people with cirrhosis and in healthy people.Journal of hepatology, 2024
After one dose, peak survodutide levels in the blood were similar in people with cirrhosis and in healthy people.Journal of hepatology, 2024

Survodutide studies on cholesterol and blood fats

2 results · people 2 · animals 0 · lab 0

2 results

In a pooled analysis of adult trials, survodutide modestly lowered total cholesterol.Diabetes, obesity & metabolism, 2025
In a pooled analysis of adult trials, survodutide modestly lowered triglycerides.Diabetes, obesity & metabolism, 2025

Survodutide studies on heart and blood vessels

1 result · people 1 · animals 0 · lab 0

1 result

In a pooled analysis of adult trials, survodutide modestly lowered blood pressure.Diabetes, obesity & metabolism, 2025

Survodutide studies on survival and serious illness

1 result · people 1 · animals 0 · lab 0

1 result

In adults with obesity, no deaths were reported in the survodutide or placebo groups of this trial.The New England journal of medicine, 2026

Survodutide studies on kidneys and bladder

6 results · people 0 · animals 6 · lab 0

Top 3 of 6 results

In mice with advanced diabetic kidney disease, survodutide gave clear benefits on protein loss in the urine.Diabetes, obesity & metabolism, 2026
In mice with advanced diabetic kidney disease, survodutide gave clear benefits on kidney filter scarring.Diabetes, obesity & metabolism, 2026
In mice with advanced diabetic kidney disease, survodutide gave clear benefits on kidney enlargement.Diabetes, obesity & metabolism, 2026

Survodutide studies on immune system and inflammation

1 result · people 0 · animals 1 · lab 0

1 result

In mice with advanced diabetic kidney disease, survodutide gave clear benefits on kidney inflammation.Diabetes, obesity & metabolism, 2026

Survodutide studies on metabolism and nutrition

1 result · people 0 · animals 1 · lab 0

1 result

In mice, BI 456906 raised energy use, which helped explain its stronger weight loss.Molecular metabolism, 2022

Trials and papers

Survodutide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

35 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (25 of 35)

25 of 35 trials

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2020202220242026202820302032

Ph 2
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929
30 Apr 2020 to 4 Nov 2021
Ph 2
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377
8 Mar 2021 to 7 Oct 2022
Ph 2
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT04771273
27 Apr 2021 to 21 Dec 2023
Ph 3
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864
20 Nov 2023 to 30 Jun 2026
Ph 3
SYNCHRONIZE™-1
NCT06066515
25 Nov 2023 to 20 Feb 2026
Ph 3
SYNCHRONIZE™-2
NCT06066528
27 Nov 2023 to 1 Apr 2026
Ph 3
SYNCHRONIZE™JP
NCT06176365
16 Jan 2024 to 3 Dec 2025
Ph 3
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
NCT06214741
6 Feb 2024 to 28 Jan 2026
Ph 1
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
NCT06200467
13 Mar 2024 to 22 Oct 2025
Ph 3
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
NCT06309992
2 Apr 2024 to 2 Dec 2025

Browse all 35 matching trials in the list below

25 trials · 6 ongoing · 4 not yet recruiting · 15 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT07855900

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Boehringer Ingelheimn = 350est. 7 Nov 2026 to est. 25 Jun 2028

Obesity

Trial page ClinicalTrials.govUpdated 2 Oct 2026

RecruitingPhase 3NCT06632444

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Boehringer Ingelheimn = 1,80014 Oct 2024 to est. 27 Dec 2031

Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis

Trial page ClinicalTrials.govUpdated 1 Oct 2026

RecruitingPhase 3NCT06632457

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Boehringer Ingelheimn = 1,59012 Nov 2024 to est. 5 Jun 2029

Metabolic Dysfunction Associated Steatohepatitis

Trial page ClinicalTrials.govUpdated 1 Oct 2026

CompletedPhase 3NCT06077864

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Boehringer Ingelheimn = 5,53120 Nov 2023 to 30 Jun 2026

Obesity

Trial page ClinicalTrials.govUpdated 30 Sept 2026

RecruitingPhase 3NCT07754461

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Boehringer Ingelheimn = 60024 Aug 2026 to est. 1 May 2028

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 30 Sept 2026

Not yet recruitingPhase 3NCT07850050

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

Boehringer Ingelheimn = 600est. 31 Oct 2026 to est. 26 Jul 2028

Obesity

Trial page ClinicalTrials.govUpdated 30 Sept 2026

Not yet recruitingPhase 3NCT07850063

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

Boehringer Ingelheimn = 600est. 23 Oct 2026 to est. 29 Apr 2029

Obesity · Metabolic Dysfunction-associated Steatotic Liver Disease

Trial page ClinicalTrials.govUpdated 30 Sept 2026

CompletedPhase 3NCT06066528

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Boehringer Ingelheimn = 75527 Nov 2023 to 1 Apr 2026

Obesity · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 6 Aug 2026

CompletedPhase 3NCT06176365

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

Boehringer Ingelheimn = 27416 Jan 2024 to 3 Dec 2025

Obesity

Trial page ClinicalTrials.govUpdated 30 Apr 2026

CompletedPhase 3NCT06214741

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Boehringer Ingelheimn = 3076 Feb 2024 to 28 Jan 2026

Obesity · Overweight

Trial page ClinicalTrials.govUpdated 30 Apr 2026

CompletedPhase 3NCT06309992

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

Boehringer Ingelheimn = 2182 Apr 2024 to 2 Dec 2025

Obesity · Non-Alcoholic SteatoHepatitis (NASH)

Trial page ClinicalTrials.govUpdated 30 Apr 2026

CompletedPhase 3NCT06066515

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Boehringer Ingelheimn = 72625 Nov 2023 to 20 Feb 2026

Obesity

Trial page ClinicalTrials.govUpdated 12 Mar 2026

Not yet recruitingPhase 2NCT07206290

Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

University Medical Center Groningenn = 120est. 2 Mar 2026 to est. 30 Nov 2027

Chronic Kidney Disease

Trial page ClinicalTrials.govUpdated 3 Oct 2025

CompletedPhase 2Results postedNCT04771273

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Boehringer Ingelheimn = 29527 Apr 2021 to 21 Dec 2023

Non-alcoholic Steatohepatitis (NASH)

Trial page ClinicalTrials.govUpdated 3 Dec 2024

CompletedPhase 2Results postedNCT04667377

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Boehringer Ingelheimn = 3878 Mar 2021 to 7 Oct 2022

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2023

CompletedPhase 2Results postedNCT04153929

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Boehringer Ingelheimn = 41330 Apr 2020 to 4 Nov 2021

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 29 Nov 2022

Active, not recruitingPhase 1NCT05202353

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Boehringer Ingelheimn = 291 Nov 2024 to est. 3 Feb 2027

Obesity

Trial page ClinicalTrials.govUpdated 9 Sept 2026

RecruitingPhase 1NCT07768813

A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

Boehringer Ingelheimn = 442 Sept 2026 to est. 22 Dec 2026

Healthy · Obesity

Trial page ClinicalTrials.govUpdated 9 Sept 2026

CompletedPhase 1NCT07221591

A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

Boehringer Ingelheimn = 1005 Nov 2025 to 28 Jul 2026

Healthy

Trial page ClinicalTrials.govUpdated 4 Aug 2026

CompletedPhase 1NCT07413913

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

Boehringer Ingelheimn = 563 Mar 2026 to 11 Jun 2026

Healthy · Obesity

Trial page ClinicalTrials.govUpdated 15 Jun 2026

Active, not recruitingPhase 1NCT06745284

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Boehringer Ingelheimn = 6426 Mar 2025 to est. 10 Jan 2027

Obesity

Trial page ClinicalTrials.govUpdated 12 May 2026

CompletedPhase 1NCT06200467

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Boehringer Ingelheimn = 11013 Mar 2024 to 22 Oct 2025

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 13 Mar 2026

CompletedPhase 1NCT06352411

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Boehringer Ingelheimn = 4215 May 2024 to 16 Sept 2025

Healthy · Renal Impairment

Trial page ClinicalTrials.govUpdated 13 Mar 2026

CompletedPhase 1NCT06564441

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Boehringer Ingelheimn = 341 Oct 2024 to 5 Jan 2026

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 13 Mar 2026

CompletedPhase 1NCT06772532

A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

Boehringer Ingelheimn = 3010 Feb 2025 to 10 Jun 2025

Healthy

Trial page ClinicalTrials.govUpdated 13 Mar 2026

1 more mentions it but does not test it. They are not trials of Survodutide: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

101 studies match. Retracted studies are left out.

Showing 10 of 101 studiesquery qry_2120d3693f309c85694fcb28

Studies with results

27 studies in all, 7 on this page

Randomized controlled trial · 2024

13 results

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

Sanyal et al. 2024The New England journal of medicinen = 293cited by 426

PMID 38847460DOI 10.1056/nejmoa2401755PUB-38847460

Full text at the publisher13 results where Survodutide was given

Publisher page See results (13)

Animal study (in vivo) · mouse · 2022

12 results

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.

Zimmermann et al. 2022Molecular metabolismcited by 115

PMID 36356832PMC9679702DOI 10.1016/j.molmet.2022.101633PUB-36356832

CC BY12 results where Survodutide was given

Download PDF See results (12)

Systematic review · 2025

9 results

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

Souza et al. 2025Hepatology (Baltimore, Md.)cited by 86

PMID 39903735PMC12614381DOI 10.1097/hep.0000000000001254PUB-39903735

Free to read · publisher termsCC BY-NC-ND3 results where Survodutide was given

Read at source See results (9)

Non-randomized trial · 2023

12 results

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.

Jungnik et al. 2023Diabetes, obesity & metabolismn = 80cited by 55

PMID 36527386DOI 10.1111/dom.14948PUB-36527386

Full text at the publisher12 results where Survodutide was given

Publisher page See results (12)

Non-randomized trial · 2024

9 results

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Lawitz et al. 2024Journal of hepatologyn = 41cited by 51

PMID 38857788DOI 10.1016/j.jhep.2024.06.003PUB-38857788

CC BY9 results where Survodutide was given

Download PDF See results (9)

Randomized controlled trial · 2023

13 results

A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.

Yazawa et al. 2023Diabetes, obesity & metabolismn = 36cited by 20

PMID 36974349DOI 10.1111/dom.15064PUB-36974349

Full text at the publisher13 results where Survodutide was given

Publisher page See results (13)

Animal study (in vivo) · mouse · 2024

6 results

The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.

Thomas et al. 2024Diabetes, obesity & metabolismcited by 10

PMID 38560764DOI 10.1111/dom.15551PUB-38560764

Free to read · publisher termsCC BY-NC-ND6 results where Survodutide was given

Read at source See results (6)

More studies

28 studies in all, 3 on this page

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase II · 2024

Corrected

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

le Roux et al. 2024The lancet. Diabetes & endocrinologycited by 174

PMID 38330987DOI 10.1016/s2213-8587(23)00356-xPUB-38330987

Full text at the publisher

Publisher page Read the notice

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase II · 2024

Corrected

Dose-response effects on HbA_1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

Blüher et al. 2024Diabetologiacited by 106

PMID 38095657PMC10844353DOI 10.1007/s00125-023-06053-9PUB-38095657

CC BY

Download PDF Read the notice

PubMed tag: Review · 2024

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.

Stefanakis et al. 2024Metabolism: clinical and experimentalcited by 98

PMID 39481534DOI 10.1016/j.metabol.2024.156057PUB-39481534

Full text at the publisher

Publisher page

No result for Survodutide (15 studies on this page, 46 in all)

These studies name Survodutide but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Review · 2024

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

Drucker et al. 2024Diabetes carecited by 292

PMID 38843460DOI 10.2337/dci24-0003PUB-38843460

Full text at the publisher

Publisher page

PubMed tag: Systematic Review · 2025

Emerging pharmacotherapies for obesity: A systematic review.

Kokkorakis et al. 2025Pharmacological reviewscited by 60

PMID 39952695DOI 10.1124/pharmrev.123.001045PUB-39952695

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2025

Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.

Newsome et al. 2025The Journal of clinical investigationcited by 35

PMID 40590228PMC12208534DOI 10.1172/jci186425PUB-40590228

CC BY

Download PDF

PubMed tag: review-article, Review · 2023

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon.

Jeon et al. 2023Journal of obesity & metabolic syndromecited by 33

PMID 37349257PMC10327684DOI 10.7570/jomes23032PUB-37349257

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Review, letter · 2024

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

Singh et al. 2024World journal of gastroenterologycited by 31

PMID 39735270PMC11612699DOI 10.3748/wjg.v30.i48.5205PUB-39735270

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Clinical Trial Protocol · 2025

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).

Wharton et al. 2025Obesity (Silver Spring, Md.)cited by 30

PMID 39495965PMC11664303DOI 10.1002/oby.24184PUB-39495965

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Clinical Trial Protocol · 2024

Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Kosiborod et al. 2024JACC. Heart failurecited by 29

PMID 39453356DOI 10.1016/j.jchf.2024.09.004PUB-39453356

Full text at the publisher

Publisher page

PubMed tag: Meta-Analysis, Systematic Review · 2025

32 results

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

Wang et al. 2025The Journal of clinical endocrinology and metabolismcited by 29

PMID 40489581DOI 10.1210/clinem/dgaf336PUB-40489581

Full text at the publisher32 results

Publisher page See results (32)

PubMed tag: review-article, Review · 2024

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

Gogineni et al. 2024Expert opinion on pharmacotherapycited by 26

PMID 38753454PMC11195668DOI 10.1080/14656566.2024.2356254PUB-38753454

Free to read · publisher termsCC BY-NC-ND

Read at source

PubMed tag: none · 2024

Perspectives in weight control in diabetes - Survodutide.

Klein et al. 2024Diabetes research and clinical practicecited by 21

PMID 37330144DOI 10.1016/j.diabres.2023.110779PUB-37330144

Full text at the publisher

Publisher page

PubMed tag: Review · 2025

Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.

Zafer et al. 2025Alimentary pharmacology & therapeuticscited by 21

PMID 40364529PMC12323726DOI 10.1111/apt.70196PUB-40364529

Rights unknown

Source link

PubMed tag: Review · 2025

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Bailey et al. 2025Peptidescited by 18

PMID 40081498DOI 10.1016/j.peptides.2025.171380PUB-40081498

Full text at the publisher

Publisher page

PubMed tag: Review · 2025

The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.

Alkhouri et al. 2025Expert opinion on investigational drugscited by 17

PMID 40016997DOI 10.1080/13543784.2025.2473062PUB-40016997

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2024

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.

Sidrak et al. 2024Indian journal of endocrinology and metabolismcited by 13

PMID 39676791PMC11642516DOI 10.4103/ijem.ijem_442_23PUB-39676791

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Review · 2026

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Son et al. 2026Endocrine reviewscited by 11

PMID 41054801DOI 10.1210/endrev/bnaf036PUB-41054801

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Survodutide studies: 27 papers with results

Page 1 of 1

Survodutide Once Weekly for the Treatment of Adults with Obesity.
le Roux CW · The New England journal of medicine · 2026
Randomized controlled trial · 7 results
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Sanyal AJ · The New England journal of medicine · 2024
Randomized controlled trial · 13 results
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
Wharton S · The New England journal of medicine · 2026
Randomized controlled trial · 8 results
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Ekinci EI · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 15 results
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Noureddin M · Hepatology (Baltimore, Md.) · 2026
Randomized controlled trial · 6 results
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
Yazawa R · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 13 results
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
le Roux CW · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 8 results
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
Souza M · Hepatology (Baltimore, Md.) · 2025
Systematic review · 9 results
Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
Banerjee M · Diabetes, obesity & metabolism · 2026
Systematic review · 8 results
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
Xiao YJ · Diabetes, obesity & metabolism · 2025
Systematic review · 13 results
Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.
Dutta D · Indian journal of endocrinology and metabolism · 2025
Systematic review · 10 results
Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.
Wan H · Diabetology & metabolic syndrome · 2024
Systematic review · 5 results
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Abulehia A · Endocrinology, diabetes & metabolism · 2026
Systematic review · 8 results
Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.
Awad AA · Proceedings (Baylor University. Medical Center) · 2025
Systematic review · 6 results
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Amjad MM · Diabetes, obesity & metabolism · 2026
Systematic review · 2 results
Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
Sun XY · Journal of translational medicine · 2026
Systematic review · 10 results
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
Lawitz EJ · Journal of hepatology · 2024
Non-randomized trial · 9 results
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Jungnik A · Diabetes, obesity & metabolism · 2023
Non-randomized trial · 12 results
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
Zimmermann T · Molecular metabolism · 2022
Animal study (in vivo) · mouse · 12 results
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Thomas L · Diabetes, obesity & metabolism · 2024
Animal study (in vivo) · mouse · 6 results
Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
Augustin R · Molecular metabolism · 2025
Animal study (in vivo) · mouse · 3 results
Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Hamilton A · Diabetes, obesity & metabolism · 2026
Animal study (in vivo) · mouse · 14 results
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Zimmermann T · Molecular metabolism · 2026
Animal study (in vivo) · mouse · 4 results
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Santos Solis R · Cureus · 2026
Not a test of Survodutide alone · 30 results
Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Andonie CR · Endocrinology, diabetes & metabolism · 2026
Not a test of Survodutide alone · 5 results
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Tong LH · Journal of chromatography. A · 2026
Not a test of Survodutide alone · 13 results
Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.
Puspitasari IM · Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
Not a test of Survodutide alone · 10 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate or advanced fibrosis (stages 2-3), announced by Boehringer Ingelheim and Zealand Pharma on 2024-10-08. A Fast Track designation is reported by the Zealand Pharma pipeline page; it was not confirmed in a primary source on 2026-10-09 (the Zealand page returned HTTP 403).	9 Oct 2026	Not recorded
EU	EMA	No entry in EMA medicines data (report timestamp 2026-10-09T06:23:44Z) and no EU orphan designation. EMA PRIME access for MASH with fibrosis is reported by the Zealand Pharma pipeline page and a Citeline article; it was not re-confirmed on 2026-10-09 (the Zealand page returned HTTP 403; the EMA PRIME eligibility lists that were found did not name survodutide).	9 Oct 2026	Not recorded
Sport	WADA	Banned in sport (WADA S0) S0 covers substances not approved for human use; Survodutide is not named on the List.	2026 List	wada-ama.org (opens in a new tab)
China (NMPA)	Note	Breakthrough Therapy Designation from the NMPA Center for Drug Evaluation, per the Zealand Pharma pipeline page. Not re-checked on 2026-10-09 (page returned HTTP 403) and not checked in NMPA records.	9 Oct 2026	zealandpharma.com (opens in a new tab)
Taiwan	Note	Breakthrough Designation from the Taiwan Food and Drug Administration, per the Zealand Pharma pipeline page. Not re-checked on 2026-10-09 (page returned HTTP 403).	9 Oct 2026	zealandpharma.com (opens in a new tab)

Safety outcomes

37 safety results for Survodutide.

Human evidence· 37

In adults with obesity without diabetes, no deaths were reported in the trial.
Randomized controlled trialn = 725
In adults with MASH, nausea was more frequent with survodutide than with placebo (66% vs. 23%).
Randomized controlled trialn = 293
Nausea incidence
66%
survodutide
Nausea incidence
23%
placebo
In adults with MASH, diarrhea was more frequent with survodutide than with placebo (49% vs. 23%).
Randomized controlled trialn = 293
Diarrhea incidence
49%
survodutide
Diarrhea incidence
23%
placebo
In adults with MASH, vomiting was more frequent with survodutide than with placebo (41% vs. 4%).
Randomized controlled trialn = 293
Vomiting incidence
41%
survodutide
Vomiting incidence
4%
placebo
In adults with MASH, serious adverse events occurred in 8% with survodutide and 7% with placebo.
Randomized controlled trialn = 293
Serious adverse events
8%
survodutide
Serious adverse events
7%
placebo
In adults with obesity and type 2 diabetes, gastrointestinal adverse events occurred in 77.7% of participants on survodutide 6.0 mg weekly, compared with 38.6% on placebo.
Randomized controlled trialn = 251
Participants with gastrointestinal adverse events
195 participants
survodutide 6.0 mg
Participants with gastrointestinal adverse events
77.7%
survodutide 6.0 mg
Participants with gastrointestinal adverse events
38.6%
placebo
In adults with obesity and type 2 diabetes, gastrointestinal adverse events occurred in 72.8% of participants on survodutide 3.6 mg weekly, compared with 38.6% on placebo.
Randomized controlled trialn = 250
Participants with gastrointestinal adverse events
182 participants
survodutide 3.6 mg
Participants with gastrointestinal adverse events
72.8%
survodutide 3.6 mg
Participants with gastrointestinal adverse events
38.6%
placebo
In Japanese men with overweight or obesity, 10 participants (37.0%) given BI 456906 withdrew from dose escalation due to adverse events, and none given placebo withdrew.
Randomized controlled trialn = 36
Participants withdrawn
10 participants
BI 456906
Proportion withdrawn
37%
BI 456906

The top 24 of 37 results.

Doses studied · 29

The doses that these studies used. They are not recommendations.

2.4 mg once weeklyHuman
Species
human
Route
subcutaneous
Duration
48 weeks
Design
Randomized controlled trial
4.8 mg once weeklyHuman
Species
human
Route
subcutaneous
Duration
48 weeks
Design
Randomized controlled trial
6.0 mg once weeklyHuman
Species
human
Route
subcutaneous
Duration
48 weeks
Design
Randomized controlled trial
up to 3.6 mg once weeklyHuman
Species
human
Route
subcutaneous
Duration
76 weeks
Design
Randomized controlled trial
up to 6.0 mg once weeklyHuman
Species
human
Route
subcutaneous
Duration
76 weeks
Design
Randomized controlled trial
3.6 mg once weeklyHuman
Species
human
Route
subcutaneous
Duration
76 weeks
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
2.4 mg once weekly	Human	human	subcutaneous	48 weeks	Randomized controlled trial
4.8 mg once weekly	Human	human	subcutaneous	48 weeks	Randomized controlled trial
6.0 mg once weekly	Human	human	subcutaneous	48 weeks	Randomized controlled trial
up to 3.6 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized controlled trial
up to 6.0 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized controlled trial
3.6 mg once weekly	Human	human	subcutaneous	76 weeks	Randomized controlled trial

6 of 29 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000035
Peptide version: 8
Peptide hash: 93846680e86bef42…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256779
22 Oct 2026UpdatedData version 254577
21 Oct 2026UpdatedData version 213664
14 Oct 2026UpdatedData version 194724
13 Oct 2026UpdatedData version 173565
12 Oct 2026UpdatedData version 165140

For developers

curl -s https://pepbank.io/v1/briefs/survodutide

Evidence summary for Survodutide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Body weightMetabolic and weight	Human: 38 results from 12 studies: 4 increase, 34 decrease. Strongest design: Randomized controlled trial	Animal: 4 results from 4 studies: 4 decrease. Strongest design: Animal study (in vivo)	No results	No results	42
Liver fat and liver functionLiver	Human: 28 results from 6 studies: 13 increase, 4 decrease, 11 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	29
Adverse eventsWhole body	Human: 24 results from 8 studies: 8 increase, 4 no significant change, 12 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	24
Glycemic controlMetabolic and weight	Human: 23 results from 6 studies: 2 increase, 15 decrease, 5 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 7 results from 2 studies: 5 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	30
Gastrointestinal adverse eventsGastrointestinal	Human: 12 results from 7 studies: 10 increase, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Receptor activity and mechanismPharmacology	Human: 5 results from 2 studies: 5 decrease. Strongest design: Randomized controlled trial	Animal: 11 results from 4 studies: 2 increase, 1 decrease, 8 not reported. Strongest design: Animal study (in vivo)	Lab: 2 results from 1 study: 2 not reported. Strongest design: Ex vivo tissue	No results	18
PharmacokineticsPharmacology	Human: 3 results from 2 studies: 1 increase, 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	3
LipidsCardiovascular	Human: 2 results from 1 study: 2 decrease. Strongest design: Systematic review	No results	No results	No results	2
Blood pressureCardiovascular	Human: 1 result from 1 study: 1 decrease. Strongest design: Systematic review	No results	No results	No results	1
MortalityWhole body	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1
Kidney functionKidney and urinary	No results	Animal: 6 results from 1 study: 1 increase, 1 decrease, 4 not reported. Strongest design: Animal study (in vivo)	No results	No results	6
Appetite and food intakeNervous system and cognition	No results	Animal: 2 results from 2 studies: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	2

Outcome group	Human	Animal	Lab	Computer model	Total
Body weightMetabolic and weight	Human: 38 results from 12 studies: 4 increase, 34 decrease. Strongest design: Randomized controlled trial	Animal: 4 results from 4 studies: 4 decrease. Strongest design: Animal study (in vivo)	No results	No results	42
Liver fat and liver functionLiver	Human: 28 results from 6 studies: 13 increase, 4 decrease, 11 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	29
Adverse eventsWhole body	Human: 24 results from 8 studies: 8 increase, 4 no significant change, 12 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	24
Glycemic controlMetabolic and weight	Human: 23 results from 6 studies: 2 increase, 15 decrease, 5 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 7 results from 2 studies: 5 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	30
Gastrointestinal adverse eventsGastrointestinal	Human: 12 results from 7 studies: 10 increase, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Receptor activity and mechanismPharmacology	Human: 5 results from 2 studies: 5 decrease. Strongest design: Randomized controlled trial	Animal: 11 results from 4 studies: 2 increase, 1 decrease, 8 not reported. Strongest design: Animal study (in vivo)	Lab: 2 results from 1 study: 2 not reported. Strongest design: Ex vivo tissue	No results	18
PharmacokineticsPharmacology	Human: 3 results from 2 studies: 1 increase, 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	3
LipidsCardiovascular	Human: 2 results from 1 study: 2 decrease. Strongest design: Systematic review	No results	No results	No results	2
Blood pressureCardiovascular	Human: 1 result from 1 study: 1 decrease. Strongest design: Systematic review	No results	No results	No results	1
MortalityWhole body	Human: 1 result from 1 study: 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	1
Kidney functionKidney and urinary	No results	Animal: 6 results from 1 study: 1 increase, 1 decrease, 4 not reported. Strongest design: Animal study (in vivo)	No results	No results	6
Appetite and food intakeNervous system and cognition	No results	Animal: 2 results from 2 studies: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	2

Survodutide studies and research data

Survodutide identity

Targets

Sequence and structure

Sequence

Alignment to Glucagon

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

Survodutide results by year and outcome

What the studies measured

Survodutide studies on weight and appetite

Survodutide studies on side effects

Survodutide studies on liver

Survodutide studies on blood sugar

Survodutide studies on receptors and cell signals

Survodutide studies on blood levels and clearance

Survodutide studies on cholesterol and blood fats

Survodutide studies on heart and blood vessels

Survodutide studies on survival and serious illness

Survodutide studies on kidneys and bladder

Survodutide studies on immune system and inflammation

Survodutide studies on metabolism and nutrition

Survodutide trials

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

Papers

Studies with results

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.

The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.

More studies

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

Emerging pharmacotherapies for obesity: A systematic review.

Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon.

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).

Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

Perspectives in weight control in diabetes - Survodutide.

Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Dose-response effects on HbA_1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.